Search Results
Results found for "Shane Wright"
- Addex Raises $10 Million In Equity Financing
a healthcare-focused institutional investor, pursuant to which the Company agreed to sell 3,752,202 shares in the form of 625,367 American Depositary Shares (âADSsâ) at a gross purchase price of $6.50 per ADS , which is equivalent to CHF 1.00 per share. Each ADS represents six shares. the âUnregistered Warrantsâ), as well as unregistered pre-funded warrants to purchase up to 5,478,570 shares
- Understanding Orthosteric Binding: The Key to Drug Action
The receptor may change shape upon binding, affecting how the drug interacts and how effective it will The dynamic interplay of chemical forces shapes drug effectiveness.
- Unlock the Hidden Complexity Behind GPCRsâFrom Terry Kenakinâs Vault
of GPCR-targeted drugs failânot because of poor chemistry, but because weâve misunderstood how these shape-shifting
- Early Stage Biotech Hiring: What Really Holds a Team Together When the Science Starts to Drift
The right ones also know when progress matters more than perfection. đ These signals are subtle, but
- Breaking the Myth of High and Low Affinity Sites
Yet some assumptions still shaping pharmacology workflows havenât evolved as fast as todayâs science. The analytical tools that shaped traditional affinity analysis were designed for simpler systems.
- Addex raises $4.2 million in equity financing
in the form of 550,000 American Depositary Shares (âADSsâ) at a gross purchase price of $1.70 per ADS , which is equivalent to CHF 0.27 per share. Each ADS represents six shares. agreed to issue to Armistice Capital unregistered pre-funded warrants to purchase up to 11,700,000 shares $1.69 with $0.01 payable on exercise as well as unregistered warrants to purchase up to 15,000,000 shares
- Dr. GPCR and GeneTex Partner to Engage the Community on Anti-GPCR Antibody Challenges
The collaboration reflects a shared recognition that improving data reproducibility in GPCR biology requires GPCR partnership page, evaluate the antibodies in their own experimental systems, and share their findings
- Knowing When to Walk, Knowing When to Run: Lessons from the Bench
This simple advice, passed on to Ben in grad school, has helped him stay sane, focused, and impactful Imposter Syndrome and Finding Your Place Ben shares the moment he realized he mattered, when he was
- đ° GPCR Weekly News, July 31 to August 6, 2023
Randy Hall's study: GPR37L1's role in shaping cortical astrocytes during development Dr. Want to share your project informally? Submit a 1-minute abstract video using this form.
- Crinetics Pharmaceuticals Announces Pricing Of Underwritten Common Stock Offering
endocrine-related tumors, announced today the pricing of an underwritten follow-on offering of 5,625,563 shares of its common stock at a price to the public of $22.22 per share. All of the shares to be sold in the offering are to be sold by Crinetics.
- Integrated GPCR Drug Discovery: A Structured Framework for Modern Programs
Platform selection shapes interpretation. Infrastructure influences velocity.  DrGPCR Podcast, Keyvan Sedaghat joins the conversation to explore how membrane compartmentalization shapes
- GPCR Allosteric Modulation: Why Allostery is the Engine of Drug Discovery
Terry Kenakin Monthly Ask-Me-Anything sessions A growing, curated on-demand library Opportunities to shape Scientists acting on todayâs insight will shape tomorrowâs breakthroughs. 40 years of expertise at your
- Enzyme Inhibition Pharmacology: The Hidden Gatekeepers of GPCR Drug Discovery
. â Practical insight into how enzyme activation and inhibition shape drug safety, efficacy, and design a molecule directly blocks the substrateâs access) from allosteric inhibition, which alters enzyme shape toughest pharmacology questions â from receptor bias and assay design to enzyme kinetics â and help shape
- From Technician to Trailblazer: How Sokhom Pin Designed His Own PhD Program While Working in Industry
So I designed my own PhD program,â Sokhom shared.
- Purpose-Driven Opioid Research: Catherine Demeryâs Academic Path
In this episode, Catherine reflects on how her identity as a scientist took shape, why sheâs committed That kind of street-level data shapes everything: dosing strategies that reflect actual potencies in
- Unlocking the Therapeutic Potential of Previously Undruggable GPCRs
The natural ligand of the target receptor provides an excellent scaffold, already with a size and shape Right: Orion ligand analogs are engineered to optimize transmembrane domain providing significantly increased Orionâs PROcisionXá”áŽč Platform In Orionâs discovery process, shape space at the TM domain âmessageâ site Since shape space exploration is specifically focused on the âmessageâ site in the TM domain, this means
- From One to Many: How a GPCR Curiosity Became a Field-Wide Toolkit
realization was that these small, single-transmembrane proteins werenât just chaperones; they actively shaped
- Are You Guessing or Forecasting? Master GPCR Pharmacologic Models Before Itâs Too Late
. đ Quick Wins This Week đč Tell us what matters â News Survey Your 1-minute feedback shapes what
- New Podcast, Sweet Structures & $2.2B GPCR Moves
A new commentary highlights how detergents and cholesterol shape mGluR2 activationâno ligand required
- Sign Up Now!
GPCR Summit from October 10th to the 16th is taking shape.
- Dr. Ross Bathgate becomes Scientific co-founder of LASEREDD Therapeutics
July 2022 "Iâm happy to share that Iâm starting a new position as Scientific co-founder LASEREDD Therapeutics
- GPCR Selectivity Beyond the Receptor
to more restricted receptors such as 5-HT2A â and the composition and stability of those complexes shapes These differences shape how intracellular modulators behave and what their mechanistic significance reveals
- Predicting GPCR Function: Inside the Carlsson Labâs Modeling Toolbox
Instead, it aims for useful, testable predictions that shape the next experiment. Learn from the fieldâs top innovators. đ Sharpen your translational impact. đ Connect with scientists shaping
- When Pain Becomes a Catalyst: How Personal Experience Redefined One Scientistâs Mission
This is a story about how chronic pain doesn't just shape lives â it reshapes careers.
- The Five Traps of Ignoring Kinetics
Methods to detect hidden mechanismsâmixtures, dual effects, or time-dependent inhibitionâthrough curve shapes Use curve shapes as diagnostics: flattened, biphasic, or lagging responses arenât noise.
- Decoding Olfactory GPCRs: How AlphaFold and AI Are Changing the Game
Start with our GPCR training program and get hands-on with virtual tools shaping the future of drug discovery
- Mapping Motion: Intermediate States, Deorphanization & Discovery
GPCR Symposia and dive into big ideas from top scientists, early-career researchers, and innovators shaping
- Amgen to Acquire Chemocentryx for $4 Billion in Cash
companies have entered into a definitive agreement under which Amgen will acquire ChemoCentryx for $52 per share
- Production of human A2AAR in lipid nanodiscs for 19F-NMR and single-molecule fluorescence...
We explain in detail steps shared between the two sample preparation strategies, including expression
- Dr. GPCR and Celtarys Research Join Forces to Expand Access to Innovative GPCR Tools
GPCR allows us to engage with researchers worldwide who are shaping the future of receptor-targeted therapies























